Figure 1. Longitudinal analysis of circulating αβ and γδ (Vδ1 and Vδ2) T cells before (graft) and after 30, 60, and 120 days in haplo-HSCT recipients with No-VR and CMV-R. (A) The frequency of αβ (white boxes), Vδ1 (light gray boxes), and Vδ2 (blue boxes) among CD3 + T cells in 20 haplo-HSCT re... More about this image found in Longitudinal analysis of circulating αβ and γδ (Vδ1 and Vδ2) T cells before...

Figure 2. Longitudinal unsupervised analysis of γδ T cells after 30, 60, and 120 days in haplo-HSCT recipients with no-VR and CMV-R. (A) Uniform Manifold Approximation and Projection (UMAP) (left) representation and heat map (right) of γδ T-cell landscape, representing clusters identified by Flo... More about this image found in Longitudinal unsupervised analysis of γδ T cells after 30, 60, and 120 days...

Figure 3. Plasmatic level of IL-7, IL-15, and IL1-β in haplo-HSCT recipients with no-VR and CMV-R. The plasmatic concentration of IL-7, IL-15, and IL1-b were quantified by automated enzyme-linked immunosorbent assay (ELISA) and results are shown in pg/mL: differences between patients with No-VR ... More about this image found in Plasmatic level of IL-7, IL-15, and IL1-β in haplo-HSCT recipients with no-...

Figure 4. Cytokine production by PhAg-stimulated Vδ2 T-cells in haplo-HSCT recipients with no-VR and CMV-R. (A) Representative dot plot of IFN-γ– and TNF-α–producing Vδ2 T cells after PhAg stimulation from patients with no-VR and patients with CMV-R. (B) The frequency of IFN-γ– and TNF-α–produci... More about this image found in Cytokine production by PhAg-stimulated Vδ2 T-cells in haplo-HSCT recipients...

Figure 5. Antiviral activity of soluble factors (CM) released by Vδ2 T cells. Conditioned medium obtained from resting (CM-ctrl) or PhAg-stimulated (CM-Phag) Vδ2 T cells from haplo-HSCT (n = 9) were tested for their ability to inhibit in vitro CMV replication. (A-B) The effect of CM-ctrl and CM-... More about this image found in Antiviral activity of soluble factors (CM) released by Vδ2 T cells. Condit...

Figure 6. Bystander adjuvant activity of PhAg-stimulated Vδ2 T cells. (A) Schematic representation of the in vitro model to study the Vδ2 T-cell bystander adjuvant activity on antigen presenting cell maturation (1) and on viral specific αβ T-cell response (2). (B-C) The expressions of CD86 and H... More about this image found in Bystander adjuvant activity of PhAg-stimulated Vδ2 T cells. (A) Schematic ...

Figure 7. Bystander adjuvant activity of soluble factors released by PhAg-stimulated Vδ2 T-cell lines. (A) The expression of CD86 and HLA-DR on monocytes were compared between unstimulated and CM-Vδ2–treated PBMCs from pediatric, age-matched HDs (n = 10). Differences between unstimulated and CM-... More about this image found in Bystander adjuvant activity of soluble factors released by PhAg-stimulated ...

Figure 1. Model training pipeline for all experiments. More about this image found in Model training pipeline for all experiments.

Figure 2. Comparison of cohort 1 classification performance for LogReg model trained with and without males, across early (I-II) and late stages (III-IV). High-specificity model displays sensitivity at 100% specificity, and high-sensitivity model displays specificity as 100% sensitivity. More about this image found in Comparison of cohort 1 classification performance for LogReg model trained ...